Product Images Losartan Potassium

This appears to be a chart or graph presenting data from a clinical study involving Atenolol and Losartan Potassium Tablets used to treat patients with an unspecified condition. The chart shows the study month on the X-axis and the percentage of patients with a primary endpoint on the Y-axis. An adjusted risk reduction of 13% is mentioned with a p-value of .021. Further information on the study is not available.*

This is a statistic that compares the efficacy of two different medications, atenolol and losartan potassium tablets, in reducing the risk of fatal/non-fatal stroke in patients. The adjusted risk reduction with losartan potassium tablets is 25%, which is statistically significant with a p-value of 0.001. The data is presented over a course of 66 months of the study.*

This text presents a table containing data on primary endpoint events for different demographic subgroups in a study comparing the effectiveness and safety of Losartan potassium tablets and Atenolol. The primary composite endpoint was a fatal or non-fatal stroke. The table includes subgroups based on age, gender, race, history of cardiovascular disease, Hypertension (IsH), and diabetes. The rates and hazard ratios of primary endpoint events are provided. The table concludes with information on the proportionality of symbols used in the table and the adjustment of the baseline Framingham risk score and level of electrocardiographic ventricular hypertrophy.*

The text describes a graph that displays the percentage of patients who experienced an event and the risk reduction percentage for a certain medication (Losartan Potassium Tablets) compared to a placebo. The graph displays a timeline of 48 units and shows that the medication had a 16.1% risk reduction compared to the placebo. The statistical significance is indicated by a p-value of 0.022.*

This is information about Losartan Potassium tablets, USP, manufactured by Alembic Pharmaceutical in India and sold in the United States. The usual adult dosage is not specified and is contained in accompanying material. The tablets contain 100mg of Losartan. They should be stored between 15°C to 30°C and kept in a closed container. The pharmacist is instructed to dispense with the patient information leaflet. The tablets come in a pack of 30 and are available by prescription only.*

This is information about Losartan Potassium tablets, USP, manufactured by Alembic Pharmaceutical Limited in India. The tablets contain 25mg of Losartan Potassium and the usual adult dosage information can be found in an accompanying leaflet. They should be stored at room temperature and protected from light. The product should be kept tightly closed. The packaging includes an NDC code and a GTIN.*

This is a description of a medication named Losartan Potassium. It is in tablet form and its National Drug Code (NDC) is 62332-028-30. The tablets should be stored at a controlled room temperature of 25°C (77°F) and the container should be kept tightly closed. There is a coding area that should not be printed, and the medication is produced by a company called Alembic Pharmaceuticals located in Bedminster, NJ, USA. The has also included some random characters and numbers that are not readable.*